Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | HTR1A | P08908 | 5/20 | 0.51 |
| ▸ | HTR7 | P34969 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24677569 | 0.86 | MEN1 (0.51) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL28322328 | 0.83 | AKR1C3 (0.54) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL27857403 | 0.82 | HTR1A (0.50) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL12282092 | 0.80 | MAPT (0.76) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL27662780 | 0.80 | AGXT (0.56) | ALDH1A1SMN1; SMN2MAPTLMNA | |
| SCHEMBL22892232 | 0.78 | ALDH1A1 (0.53) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL689414 | 0.77 | GPR119 (0.56) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL31642512 | 0.76 | POLB (0.52) | MEN1KMT2AALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL13063408 | 0.76 | AGXT (0.46) | ALDH1A1SMN1; SMN2MAPTHTR1AHTR7 | |
| SCHEMBL2376462 | 0.76 | CHRNA7 (0.59) | SMN1; SMN2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | PROGENICS PHARMACEUTICALS, INC. (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009151-A1 | Triazines And Related Compounds Having Antiviral Activity, Compositions And Methods Thereof | HAVCR2, ZC3HAV1, MAVS | MEN1 4840/4885KMT2A 4066/4885ALDH1A1 2382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.